Arrhythmia Management - PowerPoint PPT Presentation

1 / 28
About This Presentation
Title:

Arrhythmia Management

Description:

Title: Rhythm Disturbances Author: Dr John Bayliss Last modified by: JB Created Date: 5/14/1995 5:52:38 PM Document presentation format: 35mm Slides – PowerPoint PPT presentation

Number of Views:303
Avg rating:3.0/5.0
Slides: 29
Provided by: DrJo66
Category:

less

Transcript and Presenter's Notes

Title: Arrhythmia Management


1
Arrhythmia Management
17 Sept 2008
  • Dr John Bayliss FRCP
  • Consultant Cardiologist

2
Arrhythmia Guidelines
2006 NICE CG36 AF 2005 NSF CHD Arrhythmias 2006 BedsHertsCardiac Network Arrhythmia guidelines
www.bhcardiacnetwork.nhs.uk/std_glnsClinical.htm w
ww.westhertscardiology.com Documents/Local www.st
arpace.co.uk Clinical Specialty/Cardiovascular
www.nice.org
p 64
3
Palpitations Importance
  • Common
  • Often benign
  • Often troublesome
  • Occasionally fatal
  • Need careful assessment some/most in 1y Care
  • Need for Rapid Access Arrhythmia services
  • Early involvement of specialist clinician
  • Ablation / Device therapy increasingly effective

p 55
4
Assessment of Palpitations/Arrhythmias
  • Full History most important
  • Clinical Examination
  • Heart rate response (during after exercise)
  • 12 lead ECG (esp during symptoms)
  • Blood testsUE, Glucose, Thyroid FT, Liver FT,
    FBC

p 56-7
5
Palpitations Detailed History
  • Age of patient
  • Type and Duration of symptoms?
  • Individual thumps, misses, etc
  • Runs of tachycardia ?Regular, ?Irregular
  • Duration, Frequency
  • Onset ? Sudden/Gradual, ? Circumstances
  • Cessation ? Sudden/Gradual, ? Circumstances
  • Associated symptoms
  • ? Polyuria (due to Atrial Natriuretic Peptide
    release in Atrial tachyarrhythmias)
  • ? Collapse/Dizzy/Breathless, etc
  • Concurrent illness
  • Family History (Sudden Death, Cardiomyopathy,
    CHD)
  • Drug History (incl OTC)

p 58
6
Palpitations Low risk features
  • Manage in Primary Care
  • History
  • Not known to have heart disease
  • No family history of collapse or sudden death at
    age lt 40 years
  • No previous collapse/blackouts
  • Only infrequent attacks
  • Symptoms
  • Palpitations last lt 30 minutes
  • Missed beats ( ectopics) or brief rhythm
    irregularity only

p 57
7
Palpitations High risk features
  • Refer to Heart Rhythm Specialist
  • Pre-existing heart disease
  • Previous angina, MI, angioplasty,heart surgery
  • Clinical heart failure, or LV systolic
    dysfunction (ejection fraction lt 40)
  • Structural heart disease valve disease,
    cardiomyopathy, congenital heart disease
  • Family history of collapse or sudden death at age
    lt 40 years
  • Previous or recurrent collapse/blackouts.

p 57
8
Should GPs report 12 lead ECGs ?!
  • 24yr old woman, occasional brief flutters

9
Long QT and Brugada syndrome
  • Ion channelopathies

QTc gt450-500ms high risk of VT/SCD
10
Investigation of Arrhythmias
  • May be useful
  • Ambulatory ECG (24hr 7 days)
  • Echocardiogram
  • Exercise ECG if exercise related or ?CHD
  • Tilt Test if postural or vagal symptoms
  • Cardiac MRI - esp in young patient
  • Implantable ECG Loop Recorder (ILR, Reveal) if
    infrequent but serious events
  • Electrophysiological Study (EPS) Catheter
    Ablation therapy

11
Implantable Loop Recorder (ILR, Reveal device)
  • 15 mins daycase procedure
  • Local anaesthetic
  • implant in upper L chest
  • Battery lasts 18 months
  • High quality downloadable ECG beforeduring
    attack
  • Most cost-effective test
  • Yield 43 1
  • Cost 26 less than usual Ix 2

1Krahn AD, et al. Circ. 200110446-51. 2Krahn
AD, et al. JACC. 200342495-501.
12
Arrhythmias Treatment
  • Depends on (ECG) diagnosis !
  • S Tachy ? Cause (POTS ! heartsink)
  • A Tachy ß blocker
  • AVNRT / AVRT Ablation (Flecainide/Propafenone)
  • A Flutter Ablation (Verapamil,Dig,Amio)
  • Paroxysmal AF Sotalol, Propafenone, Flecainide
  • Permanent AF Rate v Rhythm...
  • VT ICD (ß blocker, Amio, Ablation)
  • Bradycardias Pacing

p 59
13
Catheter Ablation
  • for arrhythmias with localised anatomical
    substrate
  • often curative (no need to continue
    anti-arrhythmic Rx)

14
Device Therapy
  • Pacemakers
  • Cardiac Resynchronisation Therapy(CRT,
    Biventricular pacing)
  • Implantable Cardioverter Defibrillators (ICD)

15
Pacemakers 1958 2008 50 years
1st "Permanent" Implantable Pacemaker Bipolar
Hunter-Roth Lead (1958)
16
ICD function
  • VF terminated by single 34J shock
  • VF Dead SR
    Alive

17
(No Transcript)
18
AF Types
Aetiology
Timing
Lone AF
vs
  • 22 of PAF progress to permanent AF within 2
    years
  • 50-60 of patients are back in AF 1 year after
    cardioversion

Circulation 200110421182150
p 58
19
AF Management
  • ? Rate or Rhythm Control
  • Rate controlControl of Ventricular Rate at rest
    on exercise
  • Rhythm controlRestoration of SR Maintenance of
    SR
  • ? Anticoagulation
  • Risk of thromboembolism
  • Risk of Warfarin1-2 yearly risk of serious bleed

p 60 p 64
20
AF Rate v Rhythm control
  • Choose Rhythm Control
  • Symptomatic, Younger
  • Uncontrolled Heart Failure
  • First episode (?), or now corrected precipitant
  • DC Cardioversion
  • 3 weeks anticoagulation before 4 weeks after
  • Try to Maintain SR (50 revert to AF in 1 yr)
  • ? Need for Amiodarone / Sotalol
    Propafenone / Flecainide

p 60 p 64
21
AF Rate v Rhythm control - AFFIRM
The Atrial Fibrillation Follow-up Investigation
of Rhythm Management
n4060, age gt65, AF Mean age 69.7 Hypertension
in 71 Rate control lt80 at rest lt110 on
walk Warfarin (INR 2-3) Rhythm control
Drugs Cardioversion(s) Warfarin (INR 2-3)
unless SR for 4(-12) weeks
AFFIRM NEJM 20023471825-33
p 62
22
AF Rate v Rhythm control
  • Choose Rate Control if patient stable and if
  • Age gt65
  • Underlying CHD, Hypertension, Valve Disease
  • Anti-arrhyhtmic Rx not tolerated /
    contraindicated
  • Cardioversion inappropriate
  • Use ß Blocker firstAtenolol, Bisoprolol,
    Metoprololor rate controlling Ca blocker
    Verapamil, Diltiazem
  • Add Digoxin if necessary, or if CHF

p 60 p 64
23
IMPORTANT
  • Digoxin a drug of 2nd-3rd choice !

24
AF Digoxin Increased Mortality
  • SPORTIF IIIV (Warfarin v Ximelagatran)
  • n7329 in AF
  • Mod-high stroke risk
  • 53 on DigoxinMortality 6.5
  • 47 not on DigoxinMortality 4.1
  • Hazard ratio(adjusted for risks)1.53
  • ? ? Platelet activation

Gjesdal, K et al. Heart 200894191-196
25
AF Thromboprophylaxis
5 / year
lt3 / year
Warfarin
Aspirin
?
p 61 p 64
NICE CG36 June 2006 www.nice.org.uk
26
AF Warfarin or Aspirin
  • In AF, compared to placebo
  • Aspirin ? relative risk of stroke by 20
  • Warfarin ? relative risk of stroke by 60
  • Warfarin increases absolute annual risk of
    serious haemorrhage by 2
  • Benefit Risk
  • Echo is usually unnecessary for decision

27
CHADS2 risk score in AF
Predicts annual risk of stroke in non-rheumatic AF
Risk Score Stroke rate (95CI)
0 1.9 (1.2-3.0)
1 2.8 (2.0-3.8)
2 4.0 (3.1-5.1)
3 5.9 (4.6-7.3)
4 8.5 (6.3-11.1)
5 12.5 (8.2-17.5)
6 18.2 (10.5-27.4)
Points
CHF 1
Hypertension 1
Age 75 or older 1
Diabetes 1
Stroke or TIA 2
RISK SCORE 0 - 6
Assuming no Aspirin taken
Warfarin indicated if CHADS2 Score 2 or more
Gage BF et al JAMA 20012852864-2870
p 60-1
28
(No Transcript)
Write a Comment
User Comments (0)
About PowerShow.com